DEXTENZA VS. PREDNISOLONE ACETATE 1% Macular Edema With Diabetic Retinopathy After Cataract Surgery

Sponsor
Ophthalmic Consultants of the Capital Region (Other)
Overall Status
Recruiting
CT.gov ID
NCT04362241
Collaborator
(none)
30
Enrollment
1
Location
2
Arms
18.8
Anticipated Duration (Months)
1.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The complicated schedules for administering topical steroid eye drops combined with forgetfulness and physical difficulties instilling the drops may compromise compliance; which in turn could increase the risk for secondary complications such as PME post-cataract surgery, especially in a high-risk diabetic population. Dextenza, a sustained- release steroid insert, could help preclude adherence difficulties and provide better bioavailability, being as effective as, or more effective than steroid drops in preventing PME. The aim of this study is to assess the incidence of PME in diabetic patients undergoing cataract surgery when comparing the Dextenza insert to topical prednisolone acetate 1% drops.

Condition or DiseaseIntervention/TreatmentPhase
  • Drug: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Phase 4

Detailed Description

This prospective, open-label, single-center, randomized, fellow-eye, investigator-sponsored clinical study seeks to investigate the incidence of PME in diabetic patients with any level of background diabetic retinopathy undergoing cataract surgery treated with a 0.4mg dexamethasone intracanalicular insert when compared to standard of care prednisolone acetate 1% QID/1 week, TID/ 1 week, BID/ 1 week, QD/1 week. Topical NSAIDs will not be used in this study and all patients will receive an intracameral injection of moxifloxacin at the end of the surgical procedure. After screening a patient for inclusion and exclusion criteria, and gaining informed consent, each eye will undergo cataract surgery on separate days. The second eye will be operated on within 60 days of the first eye's surgery. One eye will be randomized to receive the dexamethasone insert using a coin flip. The other eye will be prescribed a prednisolone acetate 0.1% eye drop QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week regimen. The dexamethasone insert will be placed 2-4 days before surgery (Day -4 to Day-2) and those randomized to receive prednisolone acetate will start 2-4 days before surgery. After surgery, each eye will be followed for a period of approximately 60 days, consisting of four post-op follow-up visits (eight total post-op visits per patient). Primary and secondary endpoints will be assessed alongside standard-of-care procedures at all study visits . Adjusting for the enrollment period, the study will last a total of approximately 12 months.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This prospective study will use a fellow-eye design for 30 participants, summing to 60 eyes total. All eyes will receive cataract surgery. Per participant, one eye will be randomized to receive DEXTENZA® insertion at the end of the surgery, while the other eye will be assigned to a standard of care prednisolone acetate 1% eye drop regimen.This prospective study will use a fellow-eye design for 30 participants, summing to 60 eyes total. All eyes will receive cataract surgery. Per participant, one eye will be randomized to receive DEXTENZA® insertion at the end of the surgery, while the other eye will be assigned to a standard of care prednisolone acetate 1% eye drop regimen.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
DEXTENZA VS. PREDNISOLONE ACETATE 1% in the Incidence of Pseudophakic Macular Edema in Patients With Diabetic Retinopathy Undergoing Cataract Surgery
Actual Study Start Date :
Aug 7, 2020
Anticipated Primary Completion Date :
Feb 1, 2022
Anticipated Study Completion Date :
Mar 1, 2022

Arms and Interventions

ArmIntervention/Treatment
Experimental: Dextenza

Sustained release Dexamethasone 0.4mg

Drug: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Prednisolone Acetate 1% ophthalmic drops
Other Names:
  • Prednisolone Acetate 1%
  • Active Comparator: Prednisolone Acetate 1%

    Prednisolone Acetate Ophthalmic drops

    Drug: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
    Prednisolone Acetate 1% ophthalmic drops
    Other Names:
  • Prednisolone Acetate 1%
  • Outcome Measures

    Primary Outcome Measures

    1. To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure. [7 days]

      Percentage of eyes that developed post-surgical PME in each group measured on fluorescein angiography at Day 7 on Optical Coherence Tomography at Day 7 by a masked grader.

    2. To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure. [30 days]

      Percentage of eyes that developed post-surgical PME in each group measured on optical coherence tomography at Day 30 by a masked grader.

    3. To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure. [60 days]

      Percentage of eyes that developed post-surgical PME in each group measured on fluorescein angiography at Day 60 and on optical coherence tomography at Day 60 by a masked grader.

    Secondary Outcome Measures

    1. Incidence of central subfield thickness (CST) at Day 7 post op as seen on optical coherence tomography (OCT) [7days]

      Mean central subfield thickness (CST) at Day 7 post op in each group and comparison between groups.

    2. Incidence of central subfield thickness (CST) at Day 7 post op as seen on optical coherence tomography (OCT) [30 days]

      Mean central subfield thickness (CST) at Day 30 post op in each group and comparison between groups.

    3. Incidence of central subfield thickness (CST) at Day 60 post op as seen on optical coherence tomography (OCT) [60 days]

      Mean central subfield thickness (CST) at Day 60 post op in each group and comparison between groups.

    4. To measure the change in CST inflammation outcomes and in diabetic patients as seen on optical coherence tomography (OCT), Dextenza compared to topical prednisolone acetate 1%. [7 days]

      Mean change in CST from Baseline at Day 7, Day 30 and Day 60 and comparison between groups.

    5. To measure the change in CST inflammation outcomes and in diabetic patients as seen on optical coherence tomography (OCT), Dextenza compared to topical prednisolone acetate 1%. [30 days]

      Mean change in CST from Baseline at Day 7, Day 30 and Day 60 and comparison between groups.

    6. To measure the change in CST inflammation outcomes and in diabetic patients as seen on optical coherence tomography (OCT), Dextenza compared to topical prednisolone acetate 1%. [60 days]

      Mean change in CST from Baseline at Day 7, Day 30 and Day 60 and comparison between groups.

    7. To measure the effect of 0.4mg dexamethasone intracanalicular insert in vision in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1%. [7 days]

      Difference of mean ETDRS Best Corrected Visual Acuity (BCVA) between groups at Day 7 post op

    8. To measure the effect of 0.4mg dexamethasone intracanalicular insert in vision in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1%. [30 days]

      Difference of mean ETDRS Best Corrected Visual Acuity (BCVA) between groups at Day 30 post op

    9. To measure the effect of 0.4mg dexamethasone intracanalicular insert in vision in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1%. [60 days]

      Difference of mean ETDRS Best Corrected Visual Acuity (BCVA) between groups at Day 60 post op

    10. Difference patients with absence of anterior chamber (AC) cells at Day 7 post op [7 days]

      Percentage of patients who had absence of Anterior Chamber (AC) cells at Day 7

    11. Difference patients with absence of anterior chamber (AC) cells at Day 30 post op [30 days]

      Percentage of patients who had absence of Anterior Chamber (AC) cells at Day 30

    12. Difference patients with absence of anterior chamber (AC) cells at Day 60 post op [30 days]

      Percentage of patients who had absence of Anterior Chamber (AC) cells at Day 60

    13. Self reported patient experience of comfort [60 days]

      Self-reported patient experience of comfort (right eye vs. left eye) at Day 60.

    14. Rescue Therapy [60 days]

      Percentage of eyes rescued in each group.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Binocular

    • 18 years old

    • Any level of Background Diabetic Retinopathy

    • Cataract surgery candidate in each eye

    • Pre-operative OCT and Fluorescein Angiography showing no Macular edema

    Exclusion Criteria:
    • Participant cannot complete second eye operation within 60 days of the first cataract surgery

    • Maintains regular use of systemic or ocular steroids at time of enrollment

    • Maintains regular use of systemic or ocular non-steroidal anti-inflammatory drugs at time of enrollment

    • Anterior chamber cells present at time of enrollment

    • Recent febrile illness that precludes or delays participation for 90 days

    • Pregnancy or lactation

    • Known allergy to dexamethasone

    • Known allergy to prednisolone

    • Preexisting retinal disease including uveitis, nondiabetic retinal disease, choroidal disorders, diabetic macular edema.

    • Posterior capsule rupture or other intraoperative complication in first eye operated on

    • Amblyopia

    • Anti-VEGF injections within 6 months prior to surgery day.

    • Intraocular steroid injection within 6 months prior to surgery day.

    • Intraocular surgeries within 6 months prior to surgery day.

    • Laser photocoagulation within 30 days prior to surgery day.

    • Any type of eye inflammation

    • Any punctum inflammation or dacryocystitis

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Ophthalmic Consultants of the Capital RegionTroyNew YorkUnited States12180

    Sponsors and Collaborators

    • Ophthalmic Consultants of the Capital Region

    Investigators

    • Principal Investigator: Robert Feldman, MD, Ophthalmic Consultants of the Capital Region

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ophthalmic Consultants of the Capital Region
    ClinicalTrials.gov Identifier:
    NCT04362241
    Other Study ID Numbers:
    • OphthalmicConsultantsOC
    First Posted:
    Apr 24, 2020
    Last Update Posted:
    Aug 11, 2020
    Last Verified:
    Aug 1, 2020

    Study Results

    No Results Posted as of Aug 11, 2020